INCY - INCYTE CORP
96.92
-0.900 -0.929%
Share volume: 1,032,569
Last Updated: 04-20-2026
Business Services/Services – Research, Development, Testing Labs:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$97.82
-0.90
-0.01%
Fundamental analysis
33%
Profitability
0%
Dept financing
42%
Liquidity
75%
Performance
52%
Performance
5 Days
1.68%
1 Month
7.15%
3 Months
-7.40%
6 Months
11.02%
1 Year
70.63%
2 Year
86.67%
Key data
Stock price
$96.92
DAY RANGE
$96.58 - $98.70
52 WEEK RANGE
$57.29 - $112.29
52 WEEK CHANGE
$68.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-29-2025
Company detail
CEO: Herve Hoppenot
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Region: US
Website: incyte.com
Employees: 2,320
IPO year: 1993
Issue type: Common Stock
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Recent news